Before diving into history, a personal note. My name is Mansour Ansari. I am a retired software engineer building something quietly extraordinary from my back office in Oklahoma. After a long journey building QuantumCURE Pro™ , a quantum-enhanced cloud-native drug discovery platform, refining docking pipelines, deploying Vina workers, and experimenting with entropy sources, I arrived at a quiet realization worth sharing. I am not a chemist. I never came from academia. What I

Three years ago, while retired and in a cluttered back office at my home, I began a solo experiment driven by curiosity, using a small USB quantum random number generator sitting on my desk. What started as a technical exploration gradually evolved into something much larger: an attempt to build a fundamentally new kind of drug-discovery platform. At the core of every large-scale simulation, whether forecasting severe weather or predicting how a molecule binds to a protein,

I come from the old era of computing. I started with a clone PC back in the 80s, then upgraded to an IBM PC/AT with 640k RAM and a whopping 10 MB HD. It is still sitting in my closet, and I love to look at it sometimes. Now, 40 years later, I am designing a Cancer Drug Discovery in my back office using a modern PC. Just out of curiosity, I did some research on old drug-discovery systems/methods before PCs and wrote this post. So, from the 1960s to the 1980s, long before tool

I Didn’t Set Out to Build a Company So, here is my story. You see, when I started this journey, I wasn’t trying to build a startup. that was not in my mind. I am retired and live simple... no tension and no endless business meetings. I just wanted to code an engine with modern tools. I wasn’t chasing venture capital. I wasn’t thinking about pricing tiers, TAM, or business plans. Shoot! I am not even good at writing a business plan. I had a much simpler and much harder goal: I

Happy New Year 2026 After 6 weeks of focused work, I successfully deployed a production-grade molecular docking pipeline  (AutoDock Vina + RDKit/OpenMM stack) to Google Cloud Run , backed by Google Cloud Storage  and exposed through a clean API. This is a must-have for anyone who needs to dock compounds at scale without GPUs or Enterprise Hardware, or who uses Kubernetes and/or a DevOps team! Yes, this was built without : A DevOps team Kubernetes Persistent VMs GPUs Enterpris

As of today, I have quietly moved 478,808 virtual Compounds through a quantum-enhanced drug discovery machine in my back office in Oklahoma. Today I hit a nice milestone on the Citizen Scientist  page of QuantumCURE Pro™  and the numbers made me smile, so I’m sharing them. The Raw Numbers Compounds processed (Citizen Scientist):  478,808 Compounds that made it into the Golden List:  30 Hit rate: What does that mean? In industry, typical virtual screening or HTS hit rates ar

QuantumCURE Pro ™ screen shots - Round two of QuantumCURE pro™ software validation is officially in the books. Some people pick up fishing or golf in retirement. I enjoy those too, but for the last few years I’ve been teaching myself quantum computing, cheminformatics, and how to build full cancer drug discovery portals. Why? People ask me that a lot. My answer is simple: why not? I want to be useful, and I still have work to do. I sit in a cold Oklahoma garage, lift heavy

I saw an MIT study tonight about AI and job losses, and that is alarming. So,  AI can already replace % 11. 7% of US jobs....and workforce, but what the MIT “11.7%” really is: So, MIT + Oak Ridge built a model called the Iceberg Index  that looks at: 151M U.S. workers 900+ occupations 32,000+ skills They asked: “With AI that exists today , what fraction of current work tasks could AI technically do?” Their answer: AI is already capable of doing tasks equal to 11.7% of tot

So, I have created a nifty molecular docking engine that can stand shoulder-to-shoulder with big-pharma platforms that cost $100K per year per license. Ok, I admit I don’t have the pedigree of a 20-year vendor track record, and I’m not a biologist, but I am  very good at building complex systems and making them actually run in the real world. For the past 30 years, I’ve shipped and operated mission-critical software for video, networking, and now quantum-enhanced simulation.

Companies like Schrödinger and Atomwise have incredible platforms, but their primary business is selling software and partnering with major pharmaceutical companies. They provide powerful tools  and co-discovery services; their partners own most of the downstream pipeline and wet-lab risk. Schrödinger+1 I built QuantumCURE  with a different mission: not just to rank molecules, but to actually walk a set of compounds all the way into a wet list I own and can defend . In less t

QuantumCURE Fellowship Program Over the past year, I’ve invested more than 3,000 hours  building QuantumCURE Pro  — a platform that brings quantum entropy into drug discovery. My mission is simple: to be useful to humanity  and help accelerate the search for life-saving cancer treatments. Using scientifically validated tools, I’m screening millions of compounds from PubChem with multiple entropy sources, quantum annealing , photonic QRNG seeds , and classical PRNGs . The syst

Let's Dock! It’s been a long, astonishing road since November 2024.That’s when I decided — half out of curiosity, half out of stubbornness — to see if I could connect a quantum random number generator  on my desk to a cloud-based drug discovery engine  that could actually help find new medicines. I didn’t have a corporate lab, a research team, or venture funding. I still don't although I am looking for some to expand and scale up this cool engine I have created. Back then, ju

I am a solo researcher working from my back office, digging into the world of quantum. I work with a handful of QRNG hardware. A year of work with these devices from several hardware developers, has thought me a lot. I know how they behave their streangth and weaknesses, and how to control them using Python. But Randomness from QRNG is not same as Randomness from a Annealing Box like D-Wave quantum system or an Ion Trap system such as ionQ. So let me explain. I am here to sh

By Mansour Ansari — Founder, QuantumLaso LLC I’ve been really busy these days. Not bad for a retired software engineer who officially...

So, last year—right after the Christmas holidays—I set out on a new journey. As a retired software guy, I didn’t want to sit idle. I wanted to build something useful. Something that, in my golden years, could carry value for humanity. That journey led me into the world of quantum random number generators (QRNGs) —tiny devices in USB or PCIe format that don’t just simulate randomness, but harvest it directly from nature . After discovering the technology from CryptaLabs , I wa

What if cancer drug discovery wasn’t limited to billion-dollar pharma labs? From my back office in Oklahoma, I’ve built QuantumCURE  — a molecular docking and retrosynthesis platform that uses AI, open pipelines, and quantum entropy  to explore chemical spaces classical systems often miss. In this video, I explain: Why quantum randomness  changes the search space in simulations How docking with AutoDock Vina  and free protein prep tools (PDBFixer, PDB2PQR) works The role of A

High Performance Molecular Docking System - Citizen Scientist system And yes — I am actively searching for a viable cancer drug lead, with a better chance than most traditional approaches, because my system explores chemical spaces that classical methods often overlook. It’s been almost a year in the making. So far, oh, about 3,340 hours since November 2024. My journey started before that, learning and researching, and that goes back to the COVID-19 era. Built not by a pharm

Version 5 QuantumCURE Pro, Citizen Scientist Desktop and mobile versions --- Breaking Into New Chemical Space I'm excited to announce QuantumCURE v5, the latest and most advanced release of our quantum-powered drug discovery platform. For the first time, QuantumCURE now integrates Bemis–Murcko scaffolding — a powerful computational chemistry technique developed by Guy Bemis and Mark Murcko . This method reduces each compound to its core structural framework, stripping away si

I’ll admit—I’m a bit disappointed in humanity. For years I’ve been working on a project that pushes into new science, a path I’m deeply passionate about. But it’s not the kind of path most people want to walk. It’s rough, difficult, counterintuitive, and often dismissed as “too sci-fi.” They just don't get it. Investors don’t understand it. Some friends ridicule it. Even seasoned computer people shrug it off. Others laugh because it doesn’t fit inside the comfort zone of high